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Abstract: There is a need to evaluate oral glucose-lowering agents not only for their value in 
achieving glycemic control but also for their impact on cardiac risk factor modiﬁ  cation. This 
article reviews the evidence base for the two thiazolinediones currently available, pioglitazone 
and rosiglitazone. These drugs exert their effects through actions affecting metabolic control, 
lipid proﬁ  les, and the vascular wall. They have been shown to be as efﬁ  cacious in establishing 
glycemic control, in both monotherapy and combination therapy regimens, as more traditional 
oral agents, and may be able to sustain that control in the long term. Both thiazolidinediones 
have demonstrated favorable effects on markers of cardiovascular disease. Evidence from the 
large PROactive outcomes study suggests that pioglitazone may exert protective effects in 
patients with type 2 diabetes and macrovascular disease. Thiazolidinediones are generally well 
tolerated but they can cause weight gain, induce ﬂ  uid retention, and may contribute to bone 
loss in postmenopausal women. The place of thiazolidinediones in the management of type 2 
diabetes is well established. The potential for additional beneﬁ  ts in reducing macrovascular 
risk encourages further long-term study of these agents.
Keywords: cardiovascular disease, pioglitazone, PPAR-gamma, rosiglitazone, thiazolidin-
ediones, type 2 diabetes
Introduction
The thiazolidinediones (TZDs, or glitazones) class, which currently includes rosiglitazone 
and pioglitazone, are effective and frequently prescribed treatments for type 2 dia-
betes that complement existing treatment approaches and form an important part of 
treatment algorithms. In the decade since their introduction, the prevalence of obe-
sity, diabetes, and the metabolic syndrome has increased exponentially.1–3 Diabetes 
is also closely associated with cardiovascular disease – myocardial infarction and 
stroke are the major causes of premature death in people with diabetes, and type 2 
diabetes is considered an independent risk equivalent for developing another vascular 
event.4 The increasing prevalence of diabetes will therefore be closely followed by 
increases in cardiovascular-related morbidity and mortality. However, diabetes and 
cardiovascular disease develop only over time, providing a window of opportunity 
for interventions to prevent both diseases and/or delay their progression. As the use 
of glucose-lowering agents continues to increase and new agents appear, there is a 
growing need to evaluate products not only on the basis of their use in achieving 
glycemic control, but also in the context of their effect on global cardio-metabolic 
risk factor modiﬁ  cation.
The TZDs are a unique class of oral glucose-lowering agents that work primarily 
by activating the nuclear transcription factor peroxisome proliferator-activated receptor 
gamma (PPAR-γ), thereby turning on and off speciﬁ  c genes for the regulation of 
glucose, lipids and protein metabolism. There is now considerable research to suggest, 
that beyond reducing insulin resistance and providing durable glycemic control, the Vascular Health and Risk Management 2009:5 142
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TZDs exert a number of pleiotropic effects that may play an 
important role in the treatment of type 2 diabetes mellitus.
Documented evidence for the beneﬁ  ts of pioglitazone 
on cardiovascular outcomes in patients with type 2 diabetes 
has been provided by the results of the Prospective Pioglit-
Azone Clinical Trial In Macrovascular Events (PROactive).5 
However, there has been recent debate about the possible 
differences between the two TZDs in terms of cardiovascular 
disease outcome.6 In this context, the complex, nonoverlap-
ping mechanisms of action and impact on metabolic param-
eters such as lipid proﬁ  les of pioglitazone and rosiglitazone 
may be relevant, making it unwise to extrapolate these results 
to other drugs in the class.
It therefore seems timely to review TZDs and their place 
in the management of type 2 diabetes. This review will focus 
on what is known about TZDs as a class and the current 
clinical evidence base regarding the efﬁ  cacy and safety of 
individual agents. We consider the contemporary literature 
on TZDs, highlighting these agents’ multiple metabolic 
effects and summarizing the data relating to their clinical 
effectiveness in the management of type 2 diabetes (in terms 
of both glucose control and clinical outcomes) when used as 
monotherapy or in combination with other glucose-lowering 
agents.
Type 2 diabetes – complex 
pathogenesis
Type 2 diabetes is a complex disorder. Hyperglycemia is 
the core metabolic defect and combines with a range of 
metabolic risk factors to impart high risk for cardiovascular 
events. Insulin resistance and β-cell dysfunction both play 
important roles in the development and progression of  type 2 
diabetes.7,8 Evidence has shown, that while insulin resistance 
lays the groundwork for glucose intolerance, the progression 
to type 2 diabetes does not occur until a degree of β-cell 
dysfunction has taken place, allowing blood glucose levels to 
rise.9,10 Both defects remain closely linked with the progres-
sion of the disease – declining β-cell function is associated 
with deteriorating glycemic control11,12 and insulin resistance 
is associated with numerous risk factors for cardiovascular 
disease.13–15
TZDs – rationale for a role 
in the management of diabetes
TZDs bind to the ligand-activated transcription factor 
PPAR-γ.16 Members of the PPAR family (PPAR-α, -γ and -δ) 
play a pivotal role in the regulation of lipid metabolism and 
homeostasis and are important indirect as well as direct 
regulators of cellular insulin sensitivity. However, PPAR sub-
types appear to have highly specialized functions when acting 
on endogenous genes.17,18 Thus, PPAR-α primarily activates 
genes encoding proteins involved in fatty acid oxidation. 
PPAR-δ is ubiquitously expressed in various tissues and is 
one of the key regulators of energy homeostasis in skeletal 
muscle. PPAR-γ is expressed predominantly in adipose tis-
sue and skeletal muscle and is involved in the regulation of 
adipocyte proliferation and differentiation, as well as lipid 
storage.19 This is achieved by an increase in the number of 
insulin-sensitive small adipocytes, which leads to a transfer 
of fat distribution from visceral to subcutaneous depots. The 
effect of PPAR-γ activation is to enhance the action of insulin 
in insulin-sensitive tissue by increasing glucose uptake in 
skeletal muscle and adipose tissue and decreasing hepatic 
glucose production.
While improvements in metabolic control and lipid pro-
ﬁ  les have important effects on cardiovascular disease in 
patients with diabetes, PPAR-γ agonists also have a range 
of independent actions on the vascular wall, which impacts 
on atherogenesis.20,21 PPAR-γ is expressed in vascular and 
inﬂ  ammatory cells, where it interacts with several processes 
involved in the development and progression of  atherosclero-
sis, particularly with respect to macrophage foam cell forma-
tion and the transcriptional regulation of genes mediating the 
inﬂ  ammatory response. In preclinical studies, activation of 
PPAR-γ by TZDs acts on a number of pathogenic pathways 
implicated in the development of atherosclerosis, including 
inﬂ  ammation, oxidative stress, metalloproteinase activity, 
advanced glycation end product accumulation and activation 
of the renin–angiotensin system.22 These actions manifest as 
reduced lipid deposition in vessels.23
TZDs may also enhance β-cell function, which has 
potential implications for maintaining long-term glycemic 
control in type 2 diabetes.
Altering the natural history 
of type 2 diabetes – TZDs 
and durable glycemic control
Type 2 diabetes is a progressive condition characterized by 
a combination of two fundamental defects: insulin resistance 
and impaired β-cell function. Insulin resistance in the liver, 
muscle, and adipose tissue leads to decreased glucose uptake 
in peripheral tissues, increased hepatic glucose production, 
and increased lipolysis. Once established, insulin resistance 
remains fairly constant throughout the natural course of Vascular Health and Risk Management 2009:5 143
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type 2 diabetes; whereas declining β-cell function appears 
to be the critical factor in the disease’s progression. Early in 
the natural history of this disease, before the emergence of 
marked hyperglycemia, increased insulin secretion partially 
compensates for insulin resistance. Eventually, however, as 
β-cell function deteriorates, insulin secretion can no longer 
overcome the metabolic burden posed by insulin resistance, 
and hyperglycemia results. The presence of dual patho-
physiological defects suggests that optimal glucose-lowering 
therapy for patients with type 2 diabetes should address both 
sources of metabolic dysregulation.
The primary goal of patient management in diabetes is 
to achieve and maintain glycemic control. Initially, mono-
therapy with oral glucose-lowering agents may be effective, 
but because diabetes is a progressive disease there is a con-
tinual need to reassess and intensify therapy (either through 
dose increases or additional therapies) in order to maintain 
glycemic control over the longer term.24,25
Monotherapy
A number of trials have reported the use of TZDs as mono-
therapy and have shown signiﬁ  cant reductions in the level 
of glycated hemoglobin (HbA1c) compared with placebo. In 
randomized, double-blind, placebo-controlled studies with 
pioglitazone, mean HbA1c reductions ranged from 0.8% 
(at a 30 mg dose) to 1.6% (with 45 mg).26–28 Similar studies 
using rosiglitazone showed mean HbA1c reductions ranging 
from 0.9% (2 mg twice daily) to 1.5% (4 mg twice daily).29,30 
A meta-analysis of 23 randomized, placebo-controlled trials 
comparing monotherapy with pioglitazone or rosiglitazone 
for 12 to 26 weeks found that each drug similarly reduced 
HbA1c levels more than placebo, by 1.0% to 1.5%.31
The TZDs have also been shown to be at least as effective 
as traditional oral glucose-lowering agents (metformin and 
sulfonylureas) in achieving and maintaining good glycemic 
control. A comparison of pioglitazone (45 mg) and gliclazide 
demonstrated an HbA1c reduction of 1.4% for both drugs 
after 52 weeks of treatment.32 In another study, the effects 
of pioglitazone and gliclazide were compared for 2 years in 
567 patients.33 In patients who had received pioglitazone, 
the target HbA1c was reached more often (47.8%) than in the 
patients who had received gliclazide (37.0%).
A comparison of 45 drug-naïve patients randomized to 
treatment with rosiglitazone (4 mg twice daily), metformin, 
or placebo showed that both treatments signiﬁ  cantly reduced 
HbA1c after 26 weeks in comparison with placebo.34 Several 
randomized studies have compared pioglitazone and metfor-
min and showed a comparable reduction in HbA1c.35–39
While a number of studies comparing TZDs with 
sulfonylureas or metformin have demonstrated similar 
decreases in HbA1c after 1 year of treatment, the TZDs appear 
better able to sustain glycemic control in the long term. The A 
Diabetes Outcome Progression Trial (ADOPT) investigated 
the durability of the antihyperglycemic effects of rosiglitazone, 
metformin, and glyburide (or glibencamide [UK]) in 4360 
drug-naive patients.40 The 4-year trial found that in the long-
term rosiglitazone-treated patients experienced signiﬁ  cantly 
greater durability in terms of reduction of both HbA1c and 
fasting plasma glucose levels; albeit, the absolute differences 
in glycemic control between the rosiglitazone and metformin 
groups were small.
Pioglitazone has also demonstrated sustained glycemic 
control. Data from a 2-year extension study, in which patients 
were initially randomized to pioglitazone or gliclazide, have 
shown that the proportion of patients in the pioglitazone group 
who maintained HbA1c   8% at any time during the second 
year of treatment was higher than that in the gliclazide group 
(Figure 1).41,33 This evidence for durability of effect on 
blood glucose control with the TZDs has been recognized 
in the recently updated NICE guidelines.42 Declining β-cell 
function is the predominant reason for deterioration in glucose 
tolerance. Both rosiglitazone and pioglitazone have been 
shown to slow the rate of loss of β-cell function and improve 
insulin sensitivity to a greater extent than other currently used 
oral agents.5,40 These ﬁ  ndings are consistent with a greater 
durability of glycemic control with the TZDs.
Combination therapy with oral agents
Type 2 diabetes is a chronic disease with a progressive 
deterioration in glycemic control due to the continuing loss 
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Figure 1 Kaplan–Meier curves showing the proportion of patients in pioglitazone 
and gliclazide treatment groups not failing (HbA1c   8.0%) at various time points over 
2 years. Copyright © 2005 American Diabetes Association. From Diabetes Care®,   Vol. 28, 
2005;544–550. Reprinted with permission from The American Diabetes Association.Vascular Health and Risk Management 2009:5 144
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of β-cell function. Monotherapy for type 2 diabetes may 
therefore not be sufﬁ  cient to maintain glycemic control over 
time. Subsequent therapeutic decisions are made principally 
on the basis of the HbA1c value – a goal of  6.5% is con-
sistent with the most recent recommendations from NICE 
and the IDF.42,43
Early, aggressive control of glucose levels with combi-
nation therapy may be able to slow the decline in glycemic 
control, compared with monotherapy,44 and reduce the 
complications of diabetes. To meet the goal of achieving and 
maintaining glucose levels close to the nondiabetic range, 
current guidelines and treatment algorithms emphasize ini-
tial therapy with lifestyle intervention and metformin and 
then rapid addition of medications and transition to new 
regimens when target glycemic goals are not achieved or 
sustained.42,43,45
When selecting a therapeutic regimen, it is important 
to consider whether agents address the underlying patho-
physiology. The sulfonylureas, metformin, and TZDs act at 
different sites in the body to improve insulin secretion or to 
improve insulin action. The sulfonylureas act on the β-cells 
in the pancreas to stimulate insulin secretion. Metformin is 
an insulin sensitizer with effects on the liver and muscle. 
It decreases hepatic glucose production by inhibiting both 
gluconeogenesis and glycogenolysis, and it also increases 
the uptake and utilization of glucose by muscle tissue. The 
TZDs also improve insulin sensitivity by increasing glucose 
uptake in adipose, liver, and skeletal muscle tissue.
The advantages of combination therapy are that drugs 
with complementary modes of action can target both the 
underlying insulin resistance and β-cell dysfunction. For 
example, although both the TZDs and metformin effectively 
increase sensitivity to insulin, they have different target 
organs – metformin exerting most of its glycemic effect 
by decreasing hepatic glucose production and the TZDs by 
enhancing insulin sensitivity primarily in muscle and adipose 
tissue. As a result the two agents have additive effects, and 
the addition of a TZD to metformin can lower HbA1c by up 
to 0.8%.46,47
The combination of a sulfonylurea and a TZD is also logi-
cal as these agents exert opposing effects on β-cell function. 
The sulfonylureas focus on stimulating β-cells to secrete 
more insulin. Over time, studies have shown that chronic 
exposure to a sulfonylurea can lead to acceleration of β-cell 
apoptosis, exhaustion, or desensitization.48 The TZDs may 
attenuate this effect. Although the exact manner in which 
TZDs achieve this is not entirely understood, possible mecha-
nisms suggested by results from animal studies include direct 
or indirect reductions in lipotoxicity, prevention of decreases 
in β-cell mass via an effect on reducing apoptosis and reduced 
secretory demand, as well as a possible contribution from a 
reduction in glucotoxicity.49
To determine whether TZD-induced improvement in 
glycemic control is associated with improved β-cell function, 
53 patients with type 2 diabetes were randomized to receive a 
TZD or placebo for 4 months.50 The study examined insulin 
secretion during an oral glucose tolerance test while simul-
taneously taking into account changes in insulin sensitivity. 
Following 4 months of pioglitazone or rosiglitazone treat-
ment, β-cell glucose sensitivity, ie, the ability of the β-cell to 
respond to a given change in plasma glucose concentration, 
improved by ∼2- to 2.8-fold and remained unchanged in the 
placebo-treated groups.
Further evidence of the positive effects of pioglitazone 
and rosiglitazone therapy on β-cell function is available 
from a number of randomized, controlled trials using these 
agents as monotherapy or in combination with metformin 
or a sulfonylurea. Rosiglitazone has been shown to restore 
normal insulin secretion in individuals with impaired glucose 
tolerance51 and pioglitazone to reduce the development of 
diabetes in women of Latin American descent with a history 
of gestational diabetes by improving insulin sensitivity and 
preventing the progressive deterioration of β-cell function.52 
In the large, randomized ACT NOW study, pioglitazone 
(up to 45 mg/day) prevented the progression to diabetes in 
patients with impaired glucose tolerance by 81% compared 
with placebo at an average 2.6 years of follow-up.53 The 
rate of progression to diabetes (fasting plasma glucose  7.0 
mmol/L or higher during follow-up) was 1.5% per year 
for pioglitazone compared with 6.8% per year for placebo 
(hazard ratio 0.19, p   0.00001). Patients treated with pio-
glitazone were also more likely to return to normal glucose 
tolerance (42% versus 28% with placebo, p   0.001). These 
beneﬁ  ts appeared to be due to a greater improvement in β-cell 
function with pioglitazone (as demonstrated using a variety 
of measures). In the Diabetes REduction Assessment with 
ramipril and rosiglitazone Medication (DREAM) trial, rosi-
glitazone 8 mg administered daily for 3 years signiﬁ  cantly 
reduced progression to type 2 diabetes (by 60%) and allowed 
reversion to normoglycemia among a large proportion of 
adults with impaired fasting glucose, impaired glucose toler-
ance, or both.54 The ADOPT trial tested the hypothesis that 
rosiglitazone preserves β-cell function better than other drugs 
used as ﬁ  rst-line therapy for type 2 diabetes, thus delaying 
or preventing deterioration in glycemic control. The results 
showed that initial treatment with rosiglitazone slowed the Vascular Health and Risk Management 2009:5 145
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progression to monotherapy failure more effectively than 
either metformin or glyburide.40 In PROactive, patients 
randomized to pioglitazone had a reduced need to start taking 
insulin compared with those on placebo.5
A wealth of short- and long-term studies and literature 
reviews attest to the fact that the combined use of TZDs 
with agents such as metformin or sulfonylureas provides 
better glycemic control compared with further intensifying 
the metformin or sulfonylurea monotherapy.32,36,38,44,47,48,55–64 
A TZD−metformin combination has a powerful effect on 
reducing insulin resistance and is effective in the early stages 
of type 2 diabetes when more endogenous insulin is still 
available. This combination is also associated with minimal 
hypoglycemia and less weight gain. A sulfonylurea–TZD 
combination offers the added beneﬁ  t of lowered insulin 
resistance and potential improvement in β-cell function. The 
combination of pioglitazone or rosiglitazone with metformin 
or with a sulfonylurea has been shown to be an effective alter-
native to combined metformin and sulfonylurea.38,63,65–68
The observation that early introduction of oral com-
bination therapy is more effective in achieving glycemic 
control than increasing doses of metformin or sulfonylurea 
monotherapy has prompted the introduction of ﬁ  xed-dose 
single-tablet combinations of TZDs with metformin or a 
sulfonylurea.
The clinical evidence – impact
of   TZDs on cardiovascular risk 
factors and outcomes
Diabetic dyslipidemia, characterized by increased concentra-
tions of triglycerides, reduced concentrations of high-density 
lipoprotein cholesterol (HDL-C), and increased concentra-
tions of small dense low-density lipoprotein (LDL) particles 
is a major risk factor for cardiovascular disease. The TZDs 
appear to improve this atherogenic diabetes lipid proﬁ  le, 
and a host of clinical studies have demonstrated improved 
lipid proﬁ  les with pioglitazone and to a lesser extent with 
rosiglitazone.26,28,39,66,69–72 A large meta-analysis evaluated the 
effects of rosiglitazone and pioglitazone therapies on diabetic 
dyslipidemia. Both TZDs signiﬁ  cantly raised HDL-C levels.31 
Compared with placebo, pioglitazone further improved the 
lipid proﬁ  le, signiﬁ  cantly lowering triglyceride levels and 
having a neutral effect on LDL-C and total cholesterol levels. 
In contrast, rosiglitazone was found to increase LDL-C and 
total cholesterol levels and to demonstrate a neutral effect on 
triglyceride levels. The results of the meta-analysis suggest 
that pioglitazone produces a more favorable lipid proﬁ  le. 
More recent head-to-head comparisons of the two agents have 
conﬁ  rmed these ﬁ  ndings.73,74 In the study of Goldberg et al a 
total of 802 subjects were randomized to blinded treatment 
with maximal dose of either pioglitazone or rosiglitazone 
to determine the effect of these agents on fasting lipids in 
the setting of no other glucose or lipid-lowering therapy.73 
The observed changes in lipid concentrations are shown in 
Table 1. A signiﬁ  cant difference in favor of pioglitazone 
over rosiglitazone was noted for HDL-C, triglycerides, LDL 
particle size, and LDL particle concentration.73 Furthermore, 
in an open-label study, patients with type 2 diabetes dem-
onstrated marked improvements in lipid proﬁ  les along with 
stable glycemic control after treatment conversion from 
rosiglitazone to pioglitazone while maintaining stable statin 
therapy.72 In addition, pioglitazone but not rosiglitazone 
therapy signiﬁ  cantly increased LDL-C particle size to large, 
less-atherogenic particles.39,72,75–77
The TZDs have demonstrated favorable effects on other 
surrogate markers of cardiovascular disease. Adipose tis-
sue produces substantial amounts of plasminogen activator 
inhibitor type-1 (PAI-1) – this when increased is an estab-
lished cardiovascular risk factor. Both rosiglitazone and 
pioglitazone have been shown to reduce levels of PAI-1.78,79 
Similarly, both agents have demonstrated signiﬁ  cantly greater 
anti-inﬂ  ammatory and antiatherogenic effects, compared 
with control agents, including reductions in C-reactive pro-
tein and matrix metalloproteinase-979,80 and increases in adi-
ponectin levels.80,81 Carotid intima-media thickness (CIMT) 
is a marker of coronary atheroscelerosis and independently 
predicts subsequent cardiovascular events. Two studies of 
pioglitazone versus glimepiride have demonstrated beneﬁ  cial 
Table 1 In the study of Goldberg et al a total of 802 subjects were 
randomized to blinded treatment with maximal dose of either pio-
glitazone or rosiglitazone to determine the effect of these agents 
on fasting lipids in the setting of no other glucose or lipid-lowering 
therapy.   The observed changes in lipid concentrations from baseline 
are shown73
Outcome 
measure
Pioglitazone 
(n = 363)
Rosiglitazone 
(n = 356)
Triglycerides, mmol/L −0.59 ± 0.09 0.15 ± 0.09
HDL-C, mmol/L 0.13 ± 0.01 0.06 ± 0.01
Non-HDL, mmol/L 0.09 ± 0.05 0.67 ± 0.05
LDL, mmol/L 0.32 ± 0.04 0.55 ± 0.04
TC, mmol/L 0.23 ± 0.05 0.73 ± 0.05
TC-to-HDL ratio −0.3 ± 0.1 0.7 ± 0.1
Apolipoprotein B, g/L 0.00 ± 0.01 0.11 ± 0.01
Notes: Data are means ± SE; p   0.001 for all outcomes measures listed here.
Abbreviations: HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density 
lipoprotein cholesterol; TC, total cholesterol.Vascular Health and Risk Management 2009:5 146
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effects on CIMT. In a 24-week study, a signiﬁ  cant reduction 
in CIMT was observed with pioglitazone,80 while the CHI-
CAGO (Carotid intima-media tHICkness in Atherosclerosis 
using pioGlitazOne) trial demonstrated that pioglitazone 
signiﬁ  cantly slowed progression of CIMT compared with 
glimepiride over an 18-month period.82
In addition to favorable effects on surrogate markers 
of cardiovascular disease, recently published data from 
the PERISCOPE trial demonstrate a signiﬁ  cant effect of 
pioglitazone on atheroma volume.83 In patients with type 2 
diabetes undergoing angiography for clinical indications, 
baseline intravascular ultrasound (IVUS) was performed to 
determine atheroma volume. A total of 543 patients were 
then randomized to pioglitazone 15 to 45 mg or glimepiride 
1 to 4 mg titrated to maximally tolerated dose by 16 weeks. 
After 18 months, IVUS of the originally examined coronary 
artery was performed in 360 participants and revealed that 
pioglitazone had prevented the progression of coronary 
atherosclerosis compared with glimepiride (Figure 2).
Improved glycemic control is linked to better clinical 
outcomes in diabetes. In addition, the TZDs have beneﬁ  cial 
effects on a number of cardiovascular risk markers. However, 
few studies have compared outcomes for glucose-lowering 
medications beyond their glucose-lowering efﬁ  cacy.
PROactive is the only large treatment trial to date 
designed a priori to examine cardiovascular endpoints in 
TZD-treated patients. In this trial, a total of 5238 patients with 
type 2 diabetes and macrovascular disease were randomized 
to receive either pioglitazone (15 to 45 mg daily) or placebo 
while continuing existing therapy with glucose-lowering 
agents, lipid-lowering medications, and antihypertensives.5 
The primary endpoint, which was a composite of all-cause 
mortality, nonfatal myocardial infarction (including silent 
infarction), stroke, acute coronary syndrome, endovascular 
or surgical intervention in the coronary or leg arteries, 
and amputation above the ankle, did not reach statistical 
signiﬁ  cance. This composite endpoint was challenging, 
however; it included procedural endpoints and was designed 
to demonstrate beneﬁ  t in multiple vascular beds – cardiac, 
cerebral, and peripheral. Pioglitazone was associated with a 
statistically signiﬁ  cant 16% reduction in the occurrence of 
the predetermined principal secondary endpoint (composite 
of all-cause mortality, nonfatal myocardial infarction, and 
stroke). This endpoint is identical or similar to primary 
composite endpoints used in many other major cardiovascular 
outcome studies.
In a prespeciﬁ  ed subgroup analysis, the PROactive 
investigators looked at stroke endpoints in patients with 
(n = 984) and without (n = 4254) a prior history of stroke.85 
Recurrent stroke was reduced by 47% in patients with a 
prior history of stroke who received pioglitazone compared 
with those administered placebo (hazard ratio 0.53; 95% CI 
0.34–0.85, p = 0.008). Similarly, in the subgroup of patients 
who had a previous myocardial infarction (n = 2445), 
pioglitazone had a statistically signiﬁ  cant beneﬁ  cial effect 
on the prespeciﬁ  ed endpoints of fatal and nonfatal myocar-
dial infarction (28% risk reduction; p = 0.045) and acute 
coronary syndrome (37% risk reduction; p = 0.035).86 As in 
other TZD trials, pioglitazone was associated with greater 
weight gain and with increased rates of edema and heart 
failure compared with placebo-treated patients, although 
mortality due to heart failure did not differ between the 
groups.86 Less robust data in the form of a meta-analysis of 
noncardiovascular endpoint trials, which included 16,390 
patients in 19 studies, provide further support for piogli-
tazone’s cardiovascular safety.87
The evidence base for rosiglitazone is less extensive, with 
no completed cardiovascular outcomes trials. Contrary to 
ﬁ  ndings with pioglitazone, a recent meta-analysis of noncar-
diovascular endpoint trials has suggested that rosiglitazone 
may be associated with an increased risk of cardiovascular 
events in patients with type 2 diabetes.88 The ﬁ  ndings war-
rant further investigation, however. In the individual large 
published trials included in the study (speciﬁ  cally DREAM 
and ADOPT), there were no increases in the rates of myo-
cardial ischemia or cardiovascular death. The ﬁ  ndings have 
also not been conﬁ  rmed by randomized prospective trials 
(including the interim analysis of the RECORD trial).58 
Rosiglitazone was also widely prescribed in two large car-
diovascular outcomes trials comparing intensive and standard 
glucose-lowering targets in type 2 diabetes that have been 
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Figure 2 In patients with type 2 diabetes and coronary artery disease, treatment with 
pioglitazone resulted in a signiﬁ  cantly lower rate of progression of coronary athero-
sclerosis compared with glimepiride. Developed from data of Nissen et al 2008.83
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published since the meta-analysis.89,90 While these trials were 
assessing a treatment strategy and not any speciﬁ  c drug, 
no evidence that rosiglitazone is associated with excess 
cardiovascular events was found.
Other large cardiovascular outcomes trials with rosi-
glitazone, such as BARI 2D, will provide further informa-
tion on the cardiovascular safety proﬁ  le of rosiglitazone. 
However, based on available data, the US Food and Drug 
Administration has concluded that the use of rosiglitazone 
for the treatment of type 2 diabetes may be associated with 
a greater risk of myocardial ischemic events than placebo, 
metformin, or sulfonylureas. The agency has added label 
warnings to the prescribing information until the results of 
long-term cardiovascular outcome trials for rosiglitazone 
become available.
Safety aspects of TZDs
Weight gain is a class effect of the TZDs either as mono-
therapy or in combination with other glucose-lowering 
agents. Most studies report an average weight gain of 3 to 
4 kg over the ﬁ  rst 6 months of TZD treatment, in line with the 
weight gain observed with sulfonylureas and insulin. Weight 
gain associated with TZDs may vary greatly depending on 
the individual and on the treatment regimen employed. In 
particular, weight gain is more pronounced when TZDs are 
combined with sulfonylureas or insulin.70,91
The most important side effects of the TZDs are ﬂ  uid 
retention (usually manifest as peripheral edema) and an 
increase in subcutaneous fat, which both contribute to weight 
gain. The individual contributions of excess ﬂ  uid and sub-
cutaneous fat to TZD-associated weight gain have not been 
conﬁ  rmed, although one study suggests that ﬂ  uid accounts 
for as much as 75% of body weight increase.92 Other studies, 
however, have estimated fat to have the greater contribution.93 
The likelihood of edema increases when TZDs are used in 
combination with insulin – patients using this combination 
should be monitored carefully. TZD-induced ﬂ  uid retention 
may cause or aggravate diabetic macular edema by increasing 
plasma volume and vascular permeability.94,95 In addition, as 
edema can be associated with new or worsened heart failure, 
these agents should be used with caution in patients with 
edema or a history of heart failure. Four recent large-scale 
outcomes studies have shown an increased risk of non-fatal 
heart failure versus comparator drugs or placebo.5,40,54,58 In 
the US, initiation of rosiglitazone and pioglitazone is con-
traindicated in patients with established New York Heart 
Association Class III or IV heart failure and both TZDs 
carry a box warning for congestive heart failure, which is 
entirely separate from the recent concerns over the increased 
myocardial ischemia risk associated with rosiglitazone. In 
Europe, heart failure at any stage is a contraindication to the 
use of TZDs.
Although the underlying mechanisms of TZD-induced 
edema remain unclear, in vitro and animal data suggest 
that PPAR-γ agonists stimulate sodium reabsorption in the 
distal nephron by upregulating the expression and the trans-
location of the collecting duct epithelial sodium channel. 
Preliminary evidence suggests that diuretic agents, such as 
spironolactone and hydrochlorothiazide, which interfere 
with the signaling of PPAR-γ in the renal distal collecting 
duct, may be an effective means of reversing TZD-induced 
ﬂ  uid retention.96
Both TZDs have been associated with reductions in mark-
ers of bone formation and reductions in bone mineral den-
sity.97–99 Preliminary analyses of the ADOPT trial revealed a 
small but signiﬁ  cant number of leg and forearm fractures in 
postmenopausal women with rosiglitazone.40 A similar ﬁ  nd-
ing has been reported for pioglitazone in an analysis carried 
out using the manufacturer’s clinical trial database.100 An 
observational study has also reported increased bone loss with 
TZD use in 160 older diabetic men,101 although the study did 
not have sufﬁ  cient power to control for potential confounders 
such as HbA1c level, use of other medications, or diabetic 
complications. With both agents, the majority of fractures 
observed were in the upper arm (humerus), hand, or foot. 
These sites of fracture are different from those associated 
with postmenopausal osteoporosis (eg, hip or spine). None 
of the studies were designed to study the effect of TZDs on 
bone and therefore multiple known risk factors for fractures 
cannot be excluded as confounding variables. However, 
as it is known that PPAR-γ activation may inﬂ  uence bone 
metabolism (for a review see Lau and Harper 2007102), future 
research should include a randomized, controlled trial in 
which fracture incidence and type of fracture are prospective 
outcome measures. Manufacturers have advised practitioners 
to consider the risk of fracture when initiating or treating 
female patients with type 2 diabetes using TZD-containing 
products.
The ﬁ  rst available medication in the TZD class, tro-
glitazone, was withdrawn from the market due to severe 
liver toxicity. Pioglitazone and rosiglitazone have not been 
associated with severe liver toxicity either as monotherapy 
or with oral antidiabetic agent or insulin combinations; 
however, it is recommended that liver enzymes are checked 
before initiating therapy in all patients and are moni-
tored periodically thereafter based on clinical judgment. Vascular Health and Risk Management 2009:5 148
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Both TZDs are contraindicated for use in patients with 
hepatic impairment.
Conclusions
A wealth of clinical data attest to the efﬁ  cacy of piogli-
tazone and rosiglitazone mono- and combination therapies 
in achieving and sustaining glycemic control, both in 
patients with newly diagnosed disease and in those with 
more advanced disease who are not well controlled on other 
therapies. Conventional glucose-lowering agents such as 
sulfonylureas or metformin are often unable to maintain 
durable glycemic control when used as monotherapy. As 
agents that can preserve β-cell function and reduce insulin 
resistance either as monotherapy or in combination, the 
TZDs address fundamental mechanisms in the develop-
ment and progression of type 2 diabetes, and complement 
existing treatments. Current data also hold the promise that 
early therapy with TZDs may decrease cardiovascular risk 
independently of glycemic control. Pioglitazone and (to a 
lesser extent) rosiglitazone have demonstrated favorable 
effects on surrogate markers of cardiovascular disease such 
as lipid proﬁ  les, inﬂ  ammatory markers, and CIMT, and 
recently published data for pioglitazone also demonstrate 
a signiﬁ  cant reduction in atheroma volume.83 Documented 
evidence for a beneﬁ  t on cardiovascular outcomes has 
been demonstrated only with pioglitazone,5 but a number 
of trials are being conducted to address the effect of TZDs 
on cardiovascular outcomes – speciﬁ  cally, prevention of 
macrovascular complications. The UKPDS showed that 
the lower the HbA1c level the lower the risk for long-term 
complications.103 Therefore attaining and maintaining 
HbA1c treatment goals is critical in the management of type 
2 diabetes.
Although generally well tolerated, TZDs can cause 
weight gain and induce ﬂ  uid retention that occasionally 
leads to a diagnosis of heart failure (in susceptible individu-
als) and may contribute to bone loss in a small number of 
postmenopausal women. Concerns over heart failure risks 
associated with TZDs in general are entirely separate from 
the concerns over the increased myocardial ischemia risk 
associated with rosiglitazone. To date, increased risk of 
cardiac ischemia has not been reported with pioglitazone. 
While the ADA and EASD urge greater caution in the 
use of TZDs, particularly in patients with heart failure, 
in the latest update to their diabetes treatment guidelines, 
pioglitazone remains a possible choice for a second-line 
agent in patients who do not achieve HbAlc levels below 7% 
with lifestyle modiﬁ  cation and metformin.104 Overall, the 
place of TZDs in the management of type 2 diabetes is 
well established and the potential for additional beneﬁ  ts 
on macrovascular risk beyond glucose-lowering efﬁ  cacy 
continue to encourage further study of the long-term effects 
of these agents.
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